Abbott Surpasses Earnings Forecasts with Medical Device Sales

Abbott pleased investors by exceeding revenue and profit expectations, thanks to a recent uptick in medical device sales. In its financial report, growth in the device segment made a significant contribution to total revenue. Additionally, the agreement with Exact met the company’s revenue forecasts. This partnership expands Abbott’s portfolio while supporting future growth potential. These developments demonstrate that Abbott’s financial performance has strengthened and its competitive advantage in the sector remains intact. For investors, the company’s robust cash flow and strategic alliances could positively influence long‑term growth expectations. This is not investment advice.

📊 ABT — Piyasa Yorumu

■ neutral · 55%

Abbott’s recent medical‑device sales surpassed earnings forecasts, a positive development for the company. However, the stock fell 4% within 24 hours and is currently trading below its 20‑day simple moving average (SMA). The relative strength index (RSI) sits at 40.8, which is not in the oversold zone, while the MACD is negative and below its signal line, suggesting short‑term resistance. A rapid rebound could occur, but technical indicators do not support the sustainability of an immediate rally. In the near term, the price may test the 20‑day SMA and, if it manages to break through subsequent resistance levels, a modest upward move could follow. Consequently, it is difficult to pinpoint a clear short‑term direction, though a slight recovery remains a possibility.

RSI 14

40.8

MACD

-1.13

24h Δ

-4.04%

Canlı Grafikler